Onkologie. 2015:9(4):190-194

Afatinib in the treatment of advanced non-small cell lung cancer

Bohdan Kadlec
Klinika nemocí plicních a tuberkulózy FN Brno

Afatinib (Giotrif®) is the first irreversible inhibitor of EGFR and other ErbB receptors (HER1–4) that has been approved for the treatment

of patients with distinct types of epidermal growth factor receptor (EGFR) mutation-positive locally advanced or metastatic non-small

cell lung cancer (NSCLC). It is an oral, once daily targeted therapy, based on the results of two large, randomized phase III clinical trials.

Compared to standard chemotherapy Afatinib demonstrated an overall survival benefit for patients with the most common type of

EGFR mutation (exon 19 deletion/L858R) and improve symptoms of the disease and the quality of life. The most common drug-related

adverse events, especially diarrhoea and skin disorders are predictable, generally manageable and reversible.

Keywords: Afatinib, NSCLC, targeted therapy

Published: September 18, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kadlec B. Afatinib in the treatment of advanced non-small cell lung cancer. Onkologie. 2015;9(4):190-194.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ferlay J, Shin HR, Bray F, et al. (December 2010). "Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008". International Journal of Cancer 127 (12): 2893-2917. doi: 10.1002/ijc.25516. PMID 21351269. Go to original source...
    2. Novotvary 2010 ČR. Statistická zdravotnická ročenka, ÚZIS ČR, NOR ČR 2010.
    3. Shepherd FA, Johnston MR, Payne D. et al. Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer. A National Cancer Institute of Canada Clinical Trial Group Study. Br J Cancer, 1998; 78: 683-685. Go to original source... Go to PubMed...
    4. Berghams T, Paesmans M, Meert AP, et al. Survival improvement in resectable non-small-cell lung cancer with (neo) adjuvant chemotherapy: Results of a meta-analysis of the literature. Lung Cancer, 2005; 49: 13-23. Go to original source... Go to PubMed...
    5. Le Chevalier T. Non-small cell lung cancer: the challenges of the next decade. Frontiers in Oncology - Thoracic Oncology, 2011. Go to original source...
    6. Aupérin A, Le Péchoux C, Pignon JP, et al. Meta-Analysis of Cisplatin/carboplatin based Concomitant Chemotherapy in non-small-cell Lung Cancer (MAC3LC) Group. Concomitant radio-chemotherapy based on platin compounds in patiens with locally advanced non-small cell lung cancer (NS-CLC): a meta-analysis of individual data from 1764 patients. Ann Oncol, 2006; 17: 473-483. Go to original source...
    7. Scagliotti GV, Parikh P, Pavel J, et al. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patiens with Advanced-Stage Non Small-Cell Lung Cancer. J Clin Oncol, 2008; 26: 3543-3551. Go to original source...
    8. Janku F, David J, et al. Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol, 2010; 7: 401-414. Go to original source... Go to PubMed...
    9. Janku F, Garrido-Laguna I, Petruželka L, et al. Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol, 2011; 6: 1601-1612. Go to original source... Go to PubMed...
    10. Travis WD, Brambilla E, Nogucci M, et al. International association for the study of lung cancer/american thoracic society. European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol, 2011; 6: 244-285. Go to original source... Go to PubMed...
    11. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21): 2129-2139. Go to original source...
    12. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304(5676): 1497-1500. Go to original source...
    13. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010; 28(5): 744-752. Go to original source... Go to PubMed...
    14. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11(6): 521-529. Go to original source... Go to PubMed...
    15. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009; 28(Suppl 1): S24-S31. Go to original source... Go to PubMed...
    16. Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25(5): 587-595. Go to original source... Go to PubMed...
    17. Mitsudomi T, Moria S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11: 121-128. Go to original source... Go to PubMed...
    18. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-2388. Go to original source...
    19. Zhou C, W Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR-mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised phase 3 study. Lancet Oncol. 2011; 12: 735-742. Go to original source...
    20. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13: 239-246. Go to original source...
    21. Yang J, Sequist L, et al. Overall survival (OS) In patients with advanced non-small cell lung cancer (NSCLC) harbouring common (Del19/L858R) Epidermal Growth Factor Receptor mutations (EGFR mut): pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6] comparing afatinib with chemotherapy. (Abstract #8004) at 2014 American Society of Clinical Oncology, 50th ASCO Annual Meeting, 30 May-3 June 2014, Chicago, IL, USA. Go to original source...
    22. Yang J, Hirsh V, Schuler M, et al. Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutations. J Clin Oncol 2013;DOI: 10.1200/JCO.2012.46.1764. Go to original source... Go to PubMed...
    23. Sequist L, Yang J, Yamamoto N, et al. Phase III Study of afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutations. J Clin Oncol 2013; DOI: 10.1200/JCO.2012.44.2806. Go to original source... Go to PubMed...
    24. Geater, SL, MD. LUX-Lung 6: Patient reported outcomes (PROs) from a randomized open-label, Phase III study in 1st-line advanced NSCLC patients (pts.) harbouring epidermal growth factor receptor (EGFR) mutations. Poster (Abstract #8061) at American Society of Clinical Oncology, Chicago, June 1, 2013. Go to original source...
    25. Wu Y, MD. LUX-Lung 6: A randomized, open-label, Phase III study of afatinib (A) vs. gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts.) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. (Abstract #8016) at American Society of Clinical Oncology, Chicago, June 2, 2013. Go to original source...
    26. Goss GD, Felip E, Cobo M, et al. A randomized, open-label, phase III trial of afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: LUX-Lung 8 (LL8). Abstract #12220 presented at the European Society for Medical Oncology (ESMO) 2014 Congress, Madrid, Spain. 26 - 30 September 2014. Go to original source...
    27. Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012; 13(5): 539-548. Go to original source...
    28. Yang JC-H, Sequist LV, Geater SL, et al. Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: findings from three trials of afatinib in EGFR mutation-positive lung cancer; Oral presentation at: World Congress on Lung Cancer; October 27-31, 2013; Sydney, Australia.
    29. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012; 13: 528-538. Go to original source...
    30. Wu JY, Yu CJ, Chang YC, et al. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 2011; 17(11): 3812-3821. Go to original source...
    31. Boehringer Ingelheim LUX-Lung 7: a phase IIb trial of afatinib (BIBW2992) versus gefitinib for the treatment of 1st line EGFR mutation positive adenocarcinoma of the lung. [Accessed October 21, 2013].
    32. Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012; 13(5): 539-548. Go to original source...
    33. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31(27): 3327-3334. Go to original source... Go to PubMed...
    34. Wu YL, Zhou C, Hu CP, et al. LUX-Lung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J Clin Oncol. 2013;31 (Suppl) abst 8016. Go to original source... Go to PubMed...
    35. FDA Summary of Safety and Effectiveness Data (SSED) [Accessed February 11, 2014]. http://www.accessdata.fda.gov/cdrh_docs/pdf12/P120022b.pdf.
    36. Yang JC-H, Sequist LV, Geater SL, et al. Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: findings from three trials of afatinib in EGFR mutation-positive lung cancer; Oral presentation at: World Congress on Lung Cancer; October 27-31, 2013; Sydney, Australia.
    37. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012; 13(5): 528-538. [PubMed] Go to original source... Go to PubMed...
    38. Jangigian Y, Groen H, Horn L, et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. Program and abstracts of the American Society of Clinical Oncology Annual Meeting and Exposition, June 3-7, 2011; Chicago, Illinois. Abstract 7525. Pharmacokinet. 2013; 52(12): 1101-1109.
    39. Zhou W, Ercan D, Chen L, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.Nature.2009; 462: 1070-1074. Go to original source... Go to PubMed...
    40. Lee HJ, Schaefer G, Heffron TP, et al. Noncovalent wild-type-sparing inhibitors of EGFR T790M.Cancer Discov.2013; 3: 168-181. Go to original source... Go to PubMed...
    41. Walter AO, Sjin RT, Haringsma HJ, et al. Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC. Cancer Discov.2013; 3: 1404-1415. Go to original source... Go to PubMed...
    42. Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.J Clin Oncol.2013; 31: 3987-3996. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.